The online version of this article (https://doi.org/10.1186/s12947-017-0120-9) contains supplementary material, which is available to authorized users.
Percutaneous mitral valve repair (PMVR) is increasingly performed in patients with severe mitral regurgitation (MR). Post-procedural MR grading is challenging and an unsettled issue. We hypothesised that the direct planimetry of vena contracta area (VCA) by 3D–transoesophageal echocardiography allows quantifying post-procedural MR and implies further prognostic relevance missed by the usual ordinal scale (grade I-IV).
Based on a single-centre PMVR registry containing 102 patients, the association of VCA reduction and patients’ functional capacity measured as six-minute walk distance (6 MW) was evaluated. 3D–colour-Doppler datasets were available before, during and 4 weeks after PMVR.
Twenty nine patients (age 77.0 ± 5.8 years) with advanced heart failure (75.9% NYHA III/IV) and severe degenerative (34%) or functional (66%) MR were eligible. VCA was reduced in all patients by PMVR (0.99 ± 0.46 cm2 vs. 0.22 ± 0.15 cm2, p < 0.0001). It remained stable after median time of 33 days (p = 0.999). 6 MW improved after the procedure (257.5 ± 82.5 m vs. 295.7 ± 96.3 m, p < 0.01). Patients with a decrease in VCA less than the median VCA reduction showed a more distinct improvement in 6 MW than patients with better technical result (p < 0.05). This paradoxical finding was driven by inferior results in very large functional MR.
VCA improves the evaluation of small residual MR. Its post-procedural values remain stable during a short-term follow-up and imply prognostic information for the patients’ physical improvement. VCA might contribute to a more substantiated estimation of treatment success in the heterogeneous functional MR group.
Additional file 1: Recommendation for intra−/post-procedural evaluation of MR (German Cardiac Society). (DOCX 28 kb)12947_2017_120_MOESM1_ESM.docx
Additional file 2: Power calculation analysis revealed sufficient power. (DOCX 26 kb)12947_2017_120_MOESM2_ESM.docx
Additional file 3: The subgroup of patients with follow-up TEE-examination 4 weeks after PMVR does not differ from the remaining study sample concerning sex, age or clinical manifestation of MR. (DOCX 23 kb)12947_2017_120_MOESM3_ESM.docx
Additional file 4: Patients’ characteristics only differ in absolute decrease of VCA before/after PMVR between the two groups defined by median VCAr as a first hint for further insights (cf. text). (DOCX 28 kb)12947_2017_120_MOESM4_ESM.docx
Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native Valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30:303–71. CrossRefPubMed
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;135:e1159–95.
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the Management of Valvular Heart Disease: the task force for the management of Valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38:2739–91. CrossRefPubMed
Boekstegers P, Hausleiter J, Baldus S, von Bardeleben R, Beucher H, Butter C, et al. Interventionelle Behandlung der Mitralklappeninsuffizienz mit dem MitraClip®-Verfahren. Kardiologe. 2013;7:91–104. CrossRef
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7. CrossRef
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Hear. J. – Cardiovasc. Imaging. 2015;16:233–71.
Toggweiler S, Zuber M, Sürder D, Biaggi P, Gstrein C, Moccetti T, et al. Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome. Open Hear. 2014;1:e000056. CrossRef
Puls M, Lubos E, Boekstegers P, von Bardeleben RS, Ouarrak T, Butter C, et al. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J. 2016;37:703–12. CrossRefPubMed
Maisano F, Franzen O, Baldus S, Schäfer U, Hausleiter J, Butter C, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62:1052–61. CrossRefPubMed
Buck T. Valvular heart disease – insufficiencies. Three-dimensional Echocardiogr. Berlin: Springer Berlin Heidelberg; 2011. p. 109–54.
Ellis PD. The essential guide to effect sizes - statistical power, meta-analysis, and the interpretation of research results. 1st ed. New York: Cambridge University Press; 2010. CrossRef
Lenhard W, Lenhard A. Calculation of effect sizes. 2016. https://www.psychometrica.de/effect_size.html. Accessed: 12 Dec 2016.
Dietl A, Stark K, Zimmermann ME, Meisinger C, Schunkert H, Birner C, et al. NT-proBNP predicts cardiovascular death in the general population independent of left ventricular mass and function: insights from a large population-based study with long-term follow-up. PLoS One. 2016;11:e0164060. CrossRefPubMedPubMedCentral
Sturla F, Redaelli A, Puppini G, Onorati F, Faggian G, Votta E. Functional and biomechanical effects of the edge-to-edge repair in the setting of mitral regurgitation: consolidated knowledge and novel tools to gain insight into its Percutaneous implementation. Cardiovasc Eng Technol. 2015;6:117–40. CrossRefPubMed
Little SH, Pirat B, Kumar R, Igo SR, McCulloch M, Hartley CJ, et al. Three-dimensional color Doppler echocardiography for direct measurement of vena contracta area in mitral regurgitation: in vitro validation and clinical experience. JACC Cardiovasc Imaging. 2008;1:695–704. CrossRefPubMedPubMedCentral
Pighi M, Estevez-Loureiro R, Maisano F, Ussia GP, Dall’Ara G, Franzen O, et al. Immediate and 12-month outcomes of ischemic versus nonischemic functional mitral regurgitation in patients treated with MitraClip (from the 2011 to 2012 pilot sentinel registry of Percutaneous edge-to-edge mitral valve repair of the European Society of Cardiology). Am J Cardiol. 2017;119:630–7. CrossRefPubMed
Enriquez-Sarano M, Bailey KR, Seward JB, Tajik AJ, Krohn MJ, Mays JM. Quantitative Doppler assessment of valvular regurgitation. Circulation [internet]. American Heart Association, Inc. 1993;87:841–8.
- 3D vena contracta area after MitraClip© procedure: precise quantification of residual mitral regurgitation and identification of prognostic information
Lars S. Maier
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II